PE20211418A1 - Receptores quimericos y metodos de uso de los mismos - Google Patents

Receptores quimericos y metodos de uso de los mismos

Info

Publication number
PE20211418A1
PE20211418A1 PE2020001605A PE2020001605A PE20211418A1 PE 20211418 A1 PE20211418 A1 PE 20211418A1 PE 2020001605 A PE2020001605 A PE 2020001605A PE 2020001605 A PE2020001605 A PE 2020001605A PE 20211418 A1 PE20211418 A1 PE 20211418A1
Authority
PE
Peru
Prior art keywords
antigen
cll
receptor
vector characterized
chimeric antigen
Prior art date
Application number
PE2020001605A
Other languages
English (en)
Inventor
Jed Wiltzius
Rodriguez Ruben Alvarez
Tara Arvedson
Alice Bakker
Lawren Wu
Original Assignee
Kite Pharma Inc
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kite Pharma Inc, Amgen Inc filed Critical Kite Pharma Inc
Publication of PE20211418A1 publication Critical patent/PE20211418A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70517—CD8
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70521—CD28, CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/15043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Abstract

La invencion se refiere a celulas inmunitarias manipuladas (tales como CAR o TCR), moleculas de union a antigenos (incluyendo, pero sin limitarse a, anticuerpos, scFvs, cadenas pesadas y/o ligeras y CDR de estas moleculas de union a antigeno) con especificidad para CLL-1. Tambien se refiere a un metodo para tratar una enfermedad o trastorno en un sujeto que lo necesite que comprende administrar al sujeto una celula inmune que comprende: un vector caracterizado por un polinucleotido que codifica para un receptor de antigeno quimerico que comprende una molecula de union a antigeno que se une especificamente a CLL-1; un receptor de antigeno quimerico; un vector caracterizado por un polinucleotido que comprende SEC. ID. especificas; o un vector caracterizado por un polinucleotido que codifica un receptor de antigeno quimerico (CAR) o receptor de celulas T (TCR) que comprende una molecula de union a antigeno que se une especificamente a CLL-1. La enfermedad o trastorno es leucemia mieloide aguda (AML), leucemia monoblastica aguda, neoplasia mieloide, sarcoma mieloide, entre otros.
PE2020001605A 2016-04-01 2017-03-31 Receptores quimericos y metodos de uso de los mismos PE20211418A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662317068P 2016-04-01 2016-04-01
PCT/US2017/025573 WO2017173384A1 (en) 2016-04-01 2017-03-31 Chimeric receptors and methods of use thereof

Publications (1)

Publication Number Publication Date
PE20211418A1 true PE20211418A1 (es) 2021-08-02

Family

ID=59960746

Family Applications (3)

Application Number Title Priority Date Filing Date
PE2018001934A PE20190356A1 (es) 2016-04-01 2017-03-31 Receptores quimericos y metodos de uso de los mismos
PE2019002307A PE20200400A1 (es) 2016-04-01 2017-03-31 Receptores quimericos y metodos de uso de los mismos
PE2020001605A PE20211418A1 (es) 2016-04-01 2017-03-31 Receptores quimericos y metodos de uso de los mismos

Family Applications Before (2)

Application Number Title Priority Date Filing Date
PE2018001934A PE20190356A1 (es) 2016-04-01 2017-03-31 Receptores quimericos y metodos de uso de los mismos
PE2019002307A PE20200400A1 (es) 2016-04-01 2017-03-31 Receptores quimericos y metodos de uso de los mismos

Country Status (32)

Country Link
US (3) US10597456B2 (es)
EP (2) EP3436030B1 (es)
JP (3) JP2019513370A (es)
KR (5) KR102120815B1 (es)
CN (2) CN113150170A (es)
AR (1) AR108066A1 (es)
AU (3) AU2017240788B2 (es)
BR (1) BR112018070260A2 (es)
CA (2) CA3019650C (es)
CL (5) CL2018002797A1 (es)
CO (1) CO2018010547A2 (es)
CR (2) CR20210084A (es)
DK (1) DK3436030T3 (es)
EA (1) EA201891992A1 (es)
ES (1) ES2930058T3 (es)
HR (1) HRP20221348T1 (es)
HU (1) HUE060645T2 (es)
IL (1) IL262041A (es)
LT (1) LT3436030T (es)
MA (1) MA43603A1 (es)
MX (2) MX2018012019A (es)
MY (1) MY197669A (es)
PE (3) PE20190356A1 (es)
PH (1) PH12018502113A1 (es)
PL (1) PL3436030T3 (es)
PT (1) PT3436030T (es)
RS (1) RS63735B1 (es)
SG (2) SG10201912519VA (es)
SI (1) SI3436030T1 (es)
TW (4) TW201803896A (es)
UA (1) UA123276C2 (es)
WO (1) WO2017173384A1 (es)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201116559D0 (en) 2011-09-26 2011-11-09 Univ Leuven Kath Novel viral replication inhibitors
US10704021B2 (en) 2012-03-15 2020-07-07 Flodesign Sonics, Inc. Acoustic perfusion devices
EP3092049A1 (en) 2014-01-08 2016-11-16 Flodesign Sonics Inc. Acoustophoresis device with dual acoustophoretic chamber
US11708572B2 (en) 2015-04-29 2023-07-25 Flodesign Sonics, Inc. Acoustic cell separation techniques and processes
US11377651B2 (en) 2016-10-19 2022-07-05 Flodesign Sonics, Inc. Cell therapy processes utilizing acoustophoresis
JOP20160086B1 (ar) 2015-05-08 2021-08-17 2 Katholieke Univ Leuven Ku Leuven Research And Development مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
JO3633B1 (ar) 2015-09-16 2020-08-27 Katholieke Univ Leuven Ku Leuven Research & Development مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
JOP20160198B1 (ar) 2015-09-16 2022-03-14 Janssen Pharmaceuticals Inc مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
MX2018011784A (es) 2016-03-31 2019-02-13 Janssen Pharmaceuticals Inc Derivados de indol sustituidos como inhibidores de la replicacion virica del dengue.
WO2017167953A1 (en) 2016-03-31 2017-10-05 Janssen Pharmaceuticals, Inc. Substituted indoline derivatives as dengue viral replication inhibitors
CN113150170A (zh) 2016-04-01 2021-07-23 凯德药业股份有限公司 嵌合受体及其方法和用途
KR102591930B1 (ko) 2016-04-01 2023-10-24 카이트 파마 인코포레이티드 Bcma 결합 분자 및 그의 사용 방법
BR112018068956A2 (pt) 2016-04-01 2019-01-22 Janssen Pharmaceuticals Inc derivados do composto indol substituídos como inibidores da replicação viral da dengue
TW202313671A (zh) 2016-04-01 2023-04-01 美商凱特製藥公司 嵌合抗原和ｔ細胞受體及使用方法
JOP20170069B1 (ar) 2016-04-01 2021-08-17 1 Janssen Pharmaceuticals Inc مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
US11214789B2 (en) 2016-05-03 2022-01-04 Flodesign Sonics, Inc. Concentration and washing of particles with acoustics
JOP20180025B1 (ar) 2017-03-31 2021-08-17 Janssen Pharmaceuticals Inc مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
JOP20180026A1 (ar) 2017-03-31 2019-01-30 Univ Leuven Kath مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
ES2929667T3 (es) 2017-05-22 2022-11-30 Janssen Pharmaceuticals Inc Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue
PE20200342A1 (es) 2017-05-22 2020-02-14 Janssen Pharmaceuticals Inc Derivados de indolina sustituidos como inhibidores de la replicacion virica de dengue
US11390655B2 (en) * 2017-11-16 2022-07-19 Kite Pharma, Inc. Modified chimeric antigen receptors and methods of use
BR112020009889A2 (pt) 2017-12-14 2020-11-03 Flodesign Sonics, Inc. acionador e controlador de transdutor acústico
CN109609533B (zh) * 2017-12-27 2020-07-10 赛德特生物科技开发有限公司 基于人源化cd276抗体的car慢病毒表达载体构建及其应用
JP2022505921A (ja) * 2018-10-26 2022-01-14 カファ セラピューティクス リミテッド Ｃｌｌ１を標的とする抗体およびその応用
PE20220495A1 (es) 2019-03-01 2022-04-07 Allogene Therapeutics Inc Receptores antigenicos quimericos y agentes de union dirigidos a dll3
WO2020227446A1 (en) * 2019-05-07 2020-11-12 The Board Of Trustees Of The Leland Stanford Junior University Enhancement of polypeptides and chimeric antigen receptors via hinge domains
BR112021026832A2 (pt) 2019-07-02 2022-05-10 Hutchinson Fred Cancer Res Vetores ad35 recombinantes e aprimoramentos da terapia gênica relacionada
EP4028031A4 (en) * 2019-09-13 2023-09-06 Memorial Sloan Kettering Cancer Center CD371 TARGETING ANTIGEN RECOGNIZING RECEPTORS AND USES THEREOF
CN113234169B (zh) * 2020-12-11 2022-11-01 广州百暨基因科技有限公司 靶向cll1嵌合抗原受体及其应用
CN113234162B (zh) * 2020-12-24 2022-05-13 四川大学华西医院 一种靶向cd133的嵌合抗原受体t细胞
CN113416713A (zh) * 2021-05-11 2021-09-21 中国农业科学院哈尔滨兽医研究所（中国动物卫生与流行病学中心哈尔滨分中心） 一种重组腺病毒的构建及其应用
WO2023147331A1 (en) 2022-01-26 2023-08-03 Mabswitch Inc. Bispecific molecule with tunable affinity to a targetted antigen
US20240091261A1 (en) 2022-08-26 2024-03-21 Kite Pharma, Inc. Immune cell function
GB202214132D0 (en) 2022-09-27 2022-11-09 Coding Bio Ltd CLL1 binding molecules

Family Cites Families (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE87659T1 (de) 1986-09-02 1993-04-15 Enzon Lab Inc Bindungsmolekuele mit einzelpolypeptidkette.
US5260203A (en) 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5728388A (en) 1989-10-03 1998-03-17 Terman; David S. Method of cancer treatment
US6319494B1 (en) 1990-12-14 2001-11-20 Cell Genesys, Inc. Chimeric chains for receptor-associated signal transduction pathways
IL104570A0 (en) 1992-03-18 1993-05-13 Yeda Res & Dev Chimeric genes and cells transformed therewith
US5869337A (en) 1993-02-12 1999-02-09 President And Fellows Of Harvard College Regulated transcription of targeted genes and other biological events
US5834266A (en) 1993-02-12 1998-11-10 President & Fellows Of Harvard College Regulated apoptosis
US5830462A (en) 1993-02-12 1998-11-03 President & Fellows Of Harvard College Regulated transcription of targeted genes and other biological events
US20030036654A1 (en) 1994-08-18 2003-02-20 Holt Dennis A. Synthetic multimerizing agents
US5827642A (en) 1994-08-31 1998-10-27 Fred Hutchinson Cancer Research Center Rapid expansion method ("REM") for in vitro propagation of T lymphocytes
US6892139B2 (en) 1999-01-29 2005-05-10 The Regents Of The University Of California Determining the functions and interactions of proteins by comparative analysis
US6406699B1 (en) 1999-10-05 2002-06-18 Gary W. Wood Composition and method of cancer antigen immunotherapy
JP2004500095A (ja) 2000-02-24 2004-01-08 エクサイト　セラピーズ，　インコーポレイテッド 細胞の同時の刺激および濃縮
US6797514B2 (en) 2000-02-24 2004-09-28 Xcyte Therapies, Inc. Simultaneous stimulation and concentration of cells
US6867041B2 (en) 2000-02-24 2005-03-15 Xcyte Therapies, Inc. Simultaneous stimulation and concentration of cells
WO2004006955A1 (en) 2001-07-12 2004-01-22 Jefferson Foote Super humanized antibodies
US20040014194A1 (en) 2002-03-27 2004-01-22 Schering Corporation Beta-secretase crystals and methods for preparing and using the same
US7446190B2 (en) * 2002-05-28 2008-11-04 Sloan-Kettering Institute For Cancer Research Nucleic acids encoding chimeric T cell receptors
US7393531B2 (en) 2003-01-21 2008-07-01 Arius Research Inc. Cytotoxicity mediation of cells evidencing surface expression of MCSP
EP2322547A1 (en) * 2003-06-25 2011-05-18 Crucell Holland B.V. Myeloid cell-specific lectin
US20130266551A1 (en) 2003-11-05 2013-10-10 St. Jude Children's Research Hospital, Inc. Chimeric receptors with 4-1bb stimulatory signaling domain
US7794890B2 (en) 2004-09-03 2010-09-14 Gm Global Technology Operations, Inc. Aligning method for repeating and non-repeating units in a fuel cell stack
US20100196336A1 (en) 2006-05-23 2010-08-05 Dongsu Park Modified dendritic cells having enhanced survival and immunogenicity and related compositions and methods
GB0700058D0 (en) 2007-01-03 2007-02-07 Scancell Aps Anti-tumor vaccine based on normal cells
WO2009051974A1 (en) 2007-10-17 2009-04-23 Nuvelo, Inc. Antibodes to cll-1
AU2009317161B2 (en) 2008-11-24 2014-09-11 Helmholtz Zentrum Munchen Deutsches Forschungszentrum Fur Gesundheit Und Umwelt Gmbh High affinity T cell receptor and use thereof
JP6061469B2 (ja) 2009-03-10 2017-01-25 バイオジェン・エムエイ・インコーポレイテッドＢｉｏｇｅｎ ＭＡ Ｉｎｃ． 抗ｂｃｍａ抗体
US8465743B2 (en) 2009-10-01 2013-06-18 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anti-vascular endothelial growth factor receptor-2 chimeric antigen receptors and use of same for the treatment of cancer
EP2501816A4 (en) 2009-11-17 2013-07-03 Basf Plant Science Co Gmbh PLANTS WITH INCREASED PERFORMANCE
US20130079246A1 (en) 2010-05-05 2013-03-28 Addex Pharma Sa Methods and Tools for Screening Agents Exhibiting an Activity on Receptors of the Tumor Necrosis Factor Receptor Superfamily
US9089520B2 (en) 2010-05-21 2015-07-28 Baylor College Of Medicine Methods for inducing selective apoptosis
EP3467101A3 (en) 2010-09-08 2019-06-19 Baylor College of Medicine Immunotherapy of brain tumor using geneticially engineered gd2-specific t cells
ES2602743T3 (es) 2010-09-08 2017-02-22 Chemotherapeutisches Forschungsinstitut Georg-Speyer-Haus Receptores de antígenos quiméricos con una región bisagra optimizada
US9845362B2 (en) 2010-10-08 2017-12-19 The University Of North Carolina At Charlotte Compositions comprising chimeric antigen receptors, T cells comprising the same, and methods of using the same
CN106220739A (zh) 2010-12-09 2016-12-14 宾夕法尼亚大学董事会 嵌合抗原受体‑修饰的t细胞治疗癌症的用途
BR112013018311A2 (pt) 2011-01-18 2017-03-21 Univ Pennsylvania sequência de ácido nucleico isolada, receptor de antígeno quimérico isolado, célula t geneticamente modificada, vetor, e, uso de uma célula t geneticamente modificada.
US9024028B2 (en) 2011-01-26 2015-05-05 Ariad Pharmaceuticals, Inc. Methods and compositions for the synthesis of multimerizing agents
KR101976882B1 (ko) 2011-03-23 2019-05-09 프레드 헛친슨 켄서 리서치 센터 세포 면역요법용 방법 및 조성물
RS64791B1 (sr) 2011-05-27 2023-11-30 Glaxo Group Ltd Bcma (cd269/tnfrsf17) - vezujući proteini
EP2532740A1 (en) 2011-06-11 2012-12-12 Michael Schmück Antigen-specific CD4+ and CD8+ central-memory T cell preparations for adoptive T cell therapy
MX2014003176A (es) 2011-09-16 2015-08-05 Univ Pennsylvania Celulas t diseñadas mediante arn para el tratamiento de cancer.
DE102012204596A1 (de) 2012-03-22 2013-09-26 Ford Global Technologies, Llc Verfahren und Vorrichtung zum Regeln der Geschwindigkeit eines Kraftfahrzeugs
CA2868121C (en) 2012-03-23 2021-06-01 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anti-mesothelin chimeric antigen receptors
AU2013243948A1 (en) 2012-04-02 2014-10-30 Moderna Therapeutics, Inc. Modified polynucleotides for the production of proteins associated with human disease
US9765342B2 (en) 2012-04-11 2017-09-19 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Chimeric antigen receptors targeting B-cell maturation antigen
US9163090B2 (en) 2012-05-07 2015-10-20 Cellerant Therapeutics, Inc. Antibodies specific for CLL-1
US9598489B2 (en) 2012-10-05 2017-03-21 The Trustees Of The Univeristy Of Pennsylvania Human alpha-folate receptor chimeric antigen receptor
US10117896B2 (en) 2012-10-05 2018-11-06 The Trustees Of The University Of Pennsylvania Use of a trans-signaling approach in chimeric antigen receptors
PL2953972T3 (pl) 2013-02-05 2021-03-08 Engmab Sàrl Metoda wyboru przeciwciał przeciwko bcma
NZ750426A (en) 2013-02-06 2020-06-26 Celgene Corp Modified t lymphocytes having improved specificity
SI3613439T1 (sl) 2013-02-15 2021-11-30 The Regents Of The University Of California Himerni antigenski receptor in postopki njegove uporabe
KR20150131218A (ko) 2013-03-14 2015-11-24 벨리쿰 파마슈티컬스, 인크. T 세포 증식의 제어 방법
CN105408473B9 (zh) 2013-05-14 2021-09-17 得克萨斯州大学***董事会 工程化嵌合抗原受体(car)t细胞的人应用
DK3027204T3 (da) 2013-07-29 2022-04-19 2Seventy Bio Inc Flerdelte signaleringsproteiner og anvendelser deraf
EP3074419B1 (en) 2013-11-25 2018-08-29 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Chimeric antigen receptors to control hiv infection
US20160376375A1 (en) 2013-11-27 2016-12-29 Baylor College Of Medicine CSGP4 - Specific Chimeric Antigen Receptor for Cancer
WO2015090229A1 (en) 2013-12-20 2015-06-25 Novartis Ag Regulatable chimeric antigen receptor
EP4215603A1 (en) 2014-02-04 2023-07-26 Kite Pharma, Inc. Methods for producing autologous t cells useful to treat b cell malignancies and other cancers and compositions thereof
EP3104866A4 (en) 2014-02-14 2017-08-02 Bellicum Pharmaceuticals, Inc. Methods for activating t cells using an inducible chimeric polypeptide
EP3593812A3 (en) 2014-03-15 2020-05-27 Novartis AG Treatment of cancer using chimeric antigen receptor
CA2945620C (en) 2014-04-14 2022-12-06 Cellectis Bcma (cd269) specific chimeric antigen receptors for cancer immunotherapy
TWI718992B (zh) * 2014-07-21 2021-02-21 瑞士商諾華公司 使用cll-1嵌合抗原受體治療癌症
US10174095B2 (en) 2014-07-21 2019-01-08 Novartis Ag Nucleic acid encoding a humanized anti-BCMA chimeric antigen receptor
AU2015292590B2 (en) 2014-07-24 2020-01-16 2Seventy Bio, Inc. BCMA chimeric antigen receptors
WO2016044745A1 (en) 2014-09-19 2016-03-24 Regeneron Pharmaceuticals, Inc. Chimeric antigen receptors
IL292650B2 (en) 2014-09-19 2024-04-01 Hope City IL13RA2-targeted chimeric antigen receptor T cells
RU2727451C2 (ru) 2014-12-05 2020-07-21 Сити Оф Хоуп Т-клетки, модифицированные химерным рецептором антигена, нацеленным на cs1
DK3230321T3 (da) 2014-12-12 2019-10-28 Bluebird Bio Inc Kimære bcma-antigenreceptorer
WO2016166630A1 (en) 2015-04-13 2016-10-20 Pfizer Inc. Chimeric antigen receptors targeting b-cell maturation antigen
KR102405104B1 (ko) 2015-04-13 2022-06-07 화이자 인코포레이티드 치료 항체 및 그의 용도
IL296966A (en) 2016-04-01 2022-12-01 Amgen Inc Chimeric flt-3 receptors and methods of using them
KR102591930B1 (ko) 2016-04-01 2023-10-24 카이트 파마 인코포레이티드 Bcma 결합 분자 및 그의 사용 방법
CN113150170A (zh) 2016-04-01 2021-07-23 凯德药业股份有限公司 嵌合受体及其方法和用途
TW202313671A (zh) 2016-04-01 2023-04-01 美商凱特製藥公司 嵌合抗原和ｔ細胞受體及使用方法

Also Published As

Publication number Publication date
PH12018502113A1 (en) 2019-09-23
EP4180449A1 (en) 2023-05-17
KR20230165383A (ko) 2023-12-05
RS63735B1 (sr) 2022-12-30
AU2017240788B2 (en) 2020-04-09
LT3436030T (lt) 2022-12-12
SG11201808595WA (en) 2018-10-30
HUE060645T2 (hu) 2023-04-28
KR102608405B1 (ko) 2023-12-01
TWI792123B (zh) 2023-02-11
KR20200068750A (ko) 2020-06-15
CA3019650C (en) 2023-07-25
TW202130657A (zh) 2021-08-16
BR112018070260A2 (pt) 2019-01-29
PL3436030T3 (pl) 2022-12-19
CR20180480A (es) 2019-04-02
PE20190356A1 (es) 2019-03-07
US10597456B2 (en) 2020-03-24
MX2023002556A (es) 2023-03-22
EP3436030A1 (en) 2019-02-06
MY197669A (en) 2023-07-03
UA123276C2 (uk) 2021-03-10
EP3436030A4 (en) 2019-11-06
AU2020203990A1 (en) 2020-07-02
PT3436030T (pt) 2022-11-18
CL2019002310A1 (es) 2019-12-20
US20170283500A1 (en) 2017-10-05
MA43603A1 (fr) 2019-03-29
CO2018010547A2 (es) 2019-02-08
US20230331855A1 (en) 2023-10-19
CN109641008B (zh) 2021-03-23
TW202319537A (zh) 2023-05-16
ES2930058T3 (es) 2022-12-05
JP2020202867A (ja) 2020-12-24
KR20210089262A (ko) 2021-07-15
CL2022001873A1 (es) 2023-05-26
EP3436030B1 (en) 2022-08-24
AU2017240788A1 (en) 2018-11-01
TWI714470B (zh) 2020-12-21
MX2018012019A (es) 2019-07-10
HRP20221348T1 (hr) 2023-01-06
KR20220157517A (ko) 2022-11-29
CL2020002677A1 (es) 2021-01-29
KR102120815B1 (ko) 2020-06-12
CN113150170A (zh) 2021-07-23
JP2019513370A (ja) 2019-05-30
US20200115457A1 (en) 2020-04-16
SG10201912519VA (en) 2020-02-27
KR20180129889A (ko) 2018-12-05
AR108066A1 (es) 2018-07-11
DK3436030T3 (da) 2022-11-21
TW201803896A (zh) 2018-02-01
JP7451627B2 (ja) 2024-03-18
EA201891992A1 (ru) 2019-08-30
IL262041A (en) 2018-11-29
CN109641008A (zh) 2019-04-16
PE20200400A1 (es) 2020-02-26
JP2022169740A (ja) 2022-11-09
AU2023208077A1 (en) 2023-08-17
CL2018002797A1 (es) 2020-06-12
SI3436030T1 (sl) 2023-01-31
CR20210084A (es) 2021-03-26
WO2017173384A1 (en) 2017-10-05
TW202041529A (zh) 2020-11-16
CL2021001750A1 (es) 2022-01-28
CA3177398A1 (en) 2017-10-05
CA3019650A1 (en) 2017-10-05
JP7134204B2 (ja) 2022-09-09

Similar Documents

Publication Publication Date Title
PE20211418A1 (es) Receptores quimericos y metodos de uso de los mismos
PE20190120A1 (es) Moleculas de union a bcma y metodos de uso de las mismas
CO2018002360A2 (es) Anticuerpos biespecíficos contra el a-beta humano y el receptor de transferrina humano y métodos de uso
AR126242A2 (es) Tratamiento del cáncer utilizando receptores de antígenos quiméricos
CL2023002239A1 (es) Anticuerpos de b7-h4 y métodos para usarlos
PE20211887A1 (es) Receptor antigenico quimerico (car) que comprende un dominio de union a antigenos, el cual se une selectivamente a la region constante del tcr beta 1 (trbc1) o trbc2 de celulas t
EA201501109A1 (ru) Cd19-специфический химерный антигенный рецептор и его применения
PE20240218A1 (es) Anticuerpos madurados por afinidad y humanizados para fcrh5
AR106184A1 (es) Proteínas de unión a pd-1 y sus métodos de uso
PE20220495A1 (es) Receptores antigenicos quimericos y agentes de union dirigidos a dll3
JOP20180042A1 (ar) نطاقات ربط مولد ضد متوافقة مع البشر وطرق الاستخدام
AR106230A1 (es) Anticuerpos biespecíficos contra el cd20 humano y el receptor de transferrina humano y métodos de uso
MX367787B (es) Receptores de antígenos quimericos ror1 (ntrkr1) específicos para inmunoterapia del cáncer.
AR104047A1 (es) Anticuerpos anti-ceacam6 y sus usos
PE20181310A1 (es) Anticuerpos anti-il1rap, moleculas de union a antigenos biespecificas que se unen a il1rap y cd3, y usos de estos
PE20171324A1 (es) Anticuerpos heterodimericos que se unen a cd3 y a antigenos tumorales
AR117685A1 (es) Antígeno quimérico y receptores de células t y métodos de uso
AR096617A1 (es) Anticuerpos anti-tweakr y sus usos
PE20220278A1 (es) Dominios variables de anticuerpos que se dirigen al receptor nkg2d
EA201591091A1 (ru) Антигенсвязывающие белки для bcma
PE20210652A1 (es) Moleculas de union a antigeno dirigidas a her2 que comprenden 4-1bbl
PE20180249A1 (es) Anticuerpos neutralizadores anti-ccl20
EA201790816A1 (ru) Антитела, которые связываются с ccr6, и варианты применения указанных антител
PE20170667A1 (es) Anticuerpos anti-vasa y metodos de produccion y uso de los mismos
EA202191231A1 (ru) СПОСОБЫ ЛЕЧЕНИЯ ЭНДОКРИННОЙ ОФТАЛЬМОПАТИИ С ПРИМЕНЕНИЕМ АНТИ-FcRn АНТИТЕЛ